GlaxoSmithKline (GSK) has confirmed that job cuts in its neurosciences group will affect less than 50 people, but half those cuts are coming from the company's US headquarters in North Carolina.
US drugmaker Merck & Co has not found a buyer for an R&D lab operated by its MSD-Organon division may consider closing the facility, according to a number of media reports.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at PhRMA, BIO, Shire, Eli Lilly and DPT Laboratories.
The European Directorate for the Quality of Medicines & HealthCare (EQDM) has begun Phase 2 of its “track & track” anti-counterfeiting strategy and is seeking manufacturer participation.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Stabilitech, Unilife, Genocea and Amarin.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Pfizer has acquired the consumer healthcare business of Danish firm Ferrosan for an undisclosed fee in what the pharma giant says, “is an excellent strategic fit that strengthens our presence in dietary supplements”.
Israeli drugmaker Teva Pharmaceutical Industries has received a US FDA warning letter criticising laboratory operations at its manufacturing facility in Jerusalem.
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Charles River, AMRI and Synexus.
US CRO the Duke Clinical Research Institute (DCRI) has teamed up with Kaplan EduNeering to develop a training programme to meet rising global demand for qualified clinical researchers.
Supply chain strategy implementations are more likely to succeed when they have the active support of the board and senior executives, according to research.
GSK and Teva will invest in Russian drug manufacturing in response to PM Vladimir Putin’s warning that Pharmas will face restrictions if they fail to boost local production and transfer technology.
PsiOxus Therapeutics has predicted growing demand for oncolytic vaccines, citing recent industry acquisitions as evidence of the need for novel treatments for cancer.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new job for former FDA chief and Catalent packaging appointments.
FedEx has launched a new shipping service for temperature sensitive products, specifically designed for customers in the life science and biopharma industries.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at inVentiv, Icon, ICTS, OSO and Warnex.
Genzyme will build a second manufacturing plant in Geel, Belgium to ensure it has the capacity to meet demand for its Pompe disease drugs Myozyme and Lumizyme.
Cognizant will provide Eli Lilly with end-to-end IT services as part of a multi-year deal to help make Lilly’s US sales and marketing operations more effective, efficient and innovative.
One employee has died and two have been injured after an incident at Baxter International’s manufacturing facility in Atwater, California last weekend.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new job for former EMA chief and Catalent strengthening its production team.
US CRO INC Research has bought industry consulting group Avos Life Sciences, citing pharma clients’ need to maximize return on R&D and minimize risk as the key driver.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Norwich Pharmaceuticals and Prism Ideas.
Solvias says its new combined corporate office and analytical lab in Kaiseraugst, Switzerland will improve the speed and efficiency of its contract analysis services.